Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
PR Newswire —
Facility Enters Qualification to Support Late‑Stage Pivotal Manufacturing and Commercial Readiness SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced completion of Cohort...